Hikal Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 9, 2025, 8:44 pm

Competitors of Hikal Ltd

All Competitor Stocks of Hikal Ltd

Quarterly Result

Last Updated: August 20, 2025, 9:40 am

Below is a detailed analysis of the quarterly data for Hikal Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 380.00 Cr.. The value appears to be declining and may need further review. It has decreased from 552.00 Cr. (Mar 2025) to 380.00 Cr., marking a decrease of 172.00 Cr..
• For Expenses, as of Jun 2025, the value is 355.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 429.00 Cr. (Mar 2025) to 355.00 Cr., marking a decrease of 74.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Mar 2025) to 25.00 Cr., marking a decrease of 98.00 Cr..
• For OPM %, as of Jun 2025, the value is 7.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Mar 2025) to 7.00%, marking a decrease of 15.00%.
• For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 38.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Mar 2025) to -30.00 Cr., marking a decrease of 98.00 Cr..
• For Tax %, as of Jun 2025, the value is -26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to -26.00%, marking a decrease of 52.00%.
• For Net Profit, as of Jun 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to -22.00 Cr., marking a decrease of 72.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -1.82. The value appears to be declining and may need further review. It has decreased from 4.07 (Mar 2025) to -1.82, marking a decrease of 5.89.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:13 am

Growth

Last Updated: September 5, 2025, 6:05 am

Balance Sheet

Last Updated: December 10, 2025, 2:47 am

Below is a detailed analysis of the balance sheet data for Hikal Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
• For Reserves, as of Sep 2025, the value is 1,170.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,238.00 Cr. (Mar 2025) to 1,170.00 Cr., marking a decrease of 68.00 Cr..
• For Borrowings, as of Sep 2025, the value is 683.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 765.00 Cr. (Mar 2025) to 683.00 Cr., marking a decrease of 82.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 472.00 Cr.. The value appears to be improving (decreasing). It has decreased from 502.00 Cr. (Mar 2025) to 472.00 Cr., marking a decrease of 30.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 2,349.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,529.00 Cr. (Mar 2025) to 2,349.00 Cr., marking a decrease of 180.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 1,340.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,364.00 Cr. (Mar 2025) to 1,340.00 Cr., marking a decrease of 24.00 Cr..
• For CWIP, as of Sep 2025, the value is 134.00 Cr.. The value appears strong and on an upward trend. It has increased from 121.00 Cr. (Mar 2025) to 134.00 Cr., marking an increase of 13.00 Cr..
• For Investments, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
• For Other Assets, as of Sep 2025, the value is 865.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,034.00 Cr. (Mar 2025) to 865.00 Cr., marking a decrease of 169.00 Cr..
• For Total Assets, as of Sep 2025, the value is 2,349.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,529.00 Cr. (Mar 2025) to 2,349.00 Cr., marking a decrease of 180.00 Cr..

Notably, the Reserves (1,170.00 Cr.) exceed the Borrowings (683.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Hikal Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 7.36. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.36, marking an increase of 1.72.
• For Diluted EPS (Rs.), as of Mar 25, the value is 7.36. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.36, marking an increase of 1.72.
• For Cash EPS (Rs.), as of Mar 25, the value is 18.23. This value is within the healthy range. It has increased from 15.18 (Mar 24) to 18.23, marking an increase of 3.05.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 102.21. It has increased from 96.32 (Mar 24) to 102.21, marking an increase of 5.89.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 102.21. It has increased from 96.32 (Mar 24) to 102.21, marking an increase of 5.89.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 150.59. It has increased from 144.74 (Mar 24) to 150.59, marking an increase of 5.85.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 27.00. This value is within the healthy range. It has increased from 21.86 (Mar 24) to 27.00, marking an increase of 5.14.
• For PBIT / Share (Rs.), as of Mar 25, the value is 16.11. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 16.11, marking an increase of 3.79.
• For PBT / Share (Rs.), as of Mar 25, the value is 10.02. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 10.02, marking an increase of 2.27.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 7.35. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.35, marking an increase of 1.71.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.35. This value is within the healthy range. It has increased from 5.64 (Mar 24) to 7.35, marking an increase of 1.71.
• For PBDIT Margin (%), as of Mar 25, the value is 17.92. This value is within the healthy range. It has increased from 15.10 (Mar 24) to 17.92, marking an increase of 2.82.
• For PBIT Margin (%), as of Mar 25, the value is 10.70. This value is within the healthy range. It has increased from 8.51 (Mar 24) to 10.70, marking an increase of 2.19.
• For PBT Margin (%), as of Mar 25, the value is 6.65. This value is below the healthy minimum of 10. It has increased from 5.35 (Mar 24) to 6.65, marking an increase of 1.30.
• For Net Profit Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 5. It has increased from 3.90 (Mar 24) to 4.88, marking an increase of 0.98.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 8. It has increased from 3.90 (Mar 24) to 4.88, marking an increase of 0.98.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.19. This value is below the healthy minimum of 15. It has increased from 5.86 (Mar 24) to 7.19, marking an increase of 1.33.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.44. This value is within the healthy range. It has increased from 8.77 (Mar 24) to 11.44, marking an increase of 2.67.
• For Return On Assets (%), as of Mar 25, the value is 3.59. This value is below the healthy minimum of 5. It has increased from 2.79 (Mar 24) to 3.59, marking an increase of 0.80.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.29, marking a decrease of 0.06.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has decreased from 0.68 (Mar 24) to 0.60, marking a decrease of 0.08.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.74. It has increased from 0.73 (Mar 24) to 0.74, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has decreased from 1.28 (Mar 24) to 1.26, marking a decrease of 0.02.
• For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.87 (Mar 24) to 0.83, marking a decrease of 0.04.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 5.83, marking an increase of 3.23.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 21.25 (Mar 24) to 0.00, marking a decrease of 21.25.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 7.90 (Mar 24) to 0.00, marking a decrease of 7.90.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 78.75 (Mar 24) to 0.00, marking a decrease of 78.75.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 92.10 (Mar 24) to 0.00, marking a decrease of 92.10.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 4.43. This value is within the healthy range. It has decreased from 4.78 (Mar 24) to 4.43, marking a decrease of 0.35.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 3. It has decreased from 2.23 (Mar 24) to 2.21, marking a decrease of 0.02.
• For Enterprise Value (Cr.), as of Mar 25, the value is 5,685.34. It has increased from 4,058.84 (Mar 24) to 5,685.34, marking an increase of 1,626.50.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.06. This value exceeds the healthy maximum of 3. It has increased from 2.27 (Mar 24) to 3.06, marking an increase of 0.79.
• For EV / EBITDA (X), as of Mar 25, the value is 17.05. This value exceeds the healthy maximum of 15. It has increased from 15.06 (Mar 24) to 17.05, marking an increase of 1.99.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.66, marking an increase of 0.83.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 78.74 (Mar 24) to 0.00, marking a decrease of 78.74.
• For Price / BV (X), as of Mar 25, the value is 3.91. This value exceeds the healthy maximum of 3. It has increased from 2.75 (Mar 24) to 3.91, marking an increase of 1.16.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.66. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.66, marking an increase of 0.83.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness